NCT02914223

A Study to Evaluate Cenerimod in Healthy Male Subjects

Single-center, Open-label Study With 14C-radiolabeled Cenerimod to Investigate the Mass Balance, Pharmacokinetics, and Metabolism Following Single Oral Administration to Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Viatris Innovation GmbH · Industry
• Sex: Male
• Age: 45 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main objective of the study is to investigate the rate and routes of elimination of cenerimod and the mass balance in urine, feces, and expired air

Conditions

• Healthy Subjects

Interventions

Type	Name	Description
DRUG	Cenerimod	Oral formulation of cenerimod (2mg) containing 100 μCi (3.7 MBq) of 14C-radiolabeled cenerimod

Timeline

• Start date: 2016-09-01
• Primary completion: 2016-12-01
• Completion: 2016-12-01
• First posted: 2016-09-26
• Last updated: 2025-09-22

Locations

1 site across 1 country: Netherlands